Mind-NRG Successfully Completes 6 Million Euro (~8 Million USD) Series B Financing

Published: Sep 04, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GENEVA, Switzerland--(BUSINESS WIRE)--Mind-NRG, the Swiss-based company focusing on developing neuregulins to treat neurodegenerative diseases, announces the close of its Series B financing raising 6 Million EUR (~8 Million USD). The financing was led by new investor LRM, a Belgian based investor specialising in Life Sciences, along with existing investor and leading venture capital firm Index Ventures. Mind-NRG, created in 2010, is investigating the use of neuregulins in treating a variety of neurological and psychiatric disorders. The compounds are neurotrophic factors that have disease modifying potential and naturally cross the blood-brain barrier. In particular, Mind-NRG is developing NRG-101 to treat the early-stages of neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, as well as schizophrenia.

Help employers find you! Check out all the jobs and post your resume.

Back to news